During the initial days of the pandemic every country needed the Hydroxychloroquine (HCQ) for treatment against coronavirus.
It was approved by the US Food and Drug Administration (FDA) to treat or prevent malaria and some other auto-immune conditions but it is proven that it does not help in the betterment of patients hospitalised due to Covid-19.
The researchers have warned that it may cause harm to the patients.
New research results show the problems with the medication. The risks of hydroxychloroquine for patients with Covid-19 are significantly high because fatal cardiovascular conditions due to these drugs are so much higher in older patients and with existing heart disease, both of which are more frequently found in men.
Charles H. Hennekens, Professor in FAU's Schmidt College of Medicine said, "The updated randomised evidence provides even stronger support for the halt on prescribing hydroxychloroquine in the prevention or treatment of Covid-19".
He also added that the premature and avoidable deaths will continue to happen if people still take hydroxychloroquine and also avoid the public health rules which are designed to minimize the risk of infection including vaccinations and masking.